StreetAlpha.app
Home › Stocks › CABA

Cabaletta Bio, Inc. (CABA)

Healthcare
$1.02
▼ −8.11%
LAST CLOSE · NOV 17

Cabaletta Bio develops engineered T cell therapies for autoimmune diseases, with its lead candidate in clinical trials. It last closed at $1.02 on Nov 17, down 8.11% on the day. The average 12-month price target from 2 analysts is $12.00 (+1076.5% from the last close), with a high of $16.00 and a low of $8.00.

AI Auto Pilots
Is CABA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$189.5M
EPS (diluted)
−$1.33
Free cash flow
−$162.5M
Valuation
Market cap
$220.0M
215.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$299.4M
At Sep 30
Shareholder equity
$283.9M
Shares outstanding
215.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$46.3M−$46.3MFY2021FY2022: −$53.0M−$53.0MFY2022FY2023: −$67.7M−$67.7MFY2023FY2024: −$115.9M−$115.9MFY2024FY2025: −$167.9M−$167.9MFY2025

From CABA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated CABA in the past 90 days, not enough for a consensus
Average 12-month target
$12.00
▲ 1076.5% upside

Based on 2 analysts who set a price target on CABA in the past 90 days. The average target is $12.00, with a high of $16.00 and a low of $8.00, compared with the last close of $1.02.

Low $8.00Avg $12.00High $16.00
Blue marker: last close $1.02
Highest target$16.00
Average target$12.00
Lowest target$8.00
Latest rating changes
CitigroupMaintained
Nov 9Buy$8
HC Wainwright & Co.Reiterated
Sep 1Buy$16
Wells FargoMaintained
Aug 14Hold$3
DateFirmActionRatingPrice target
Nov 9CitigroupMaintainedBuy$8
Sep 1HC Wainwright & Co.ReiteratedBuy$16
Aug 14Wells FargoMaintainedHold$3
Loading…

Technical Analysis

CABA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 37% below its 20 day and 80% below its 50 day average. It is 172% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $0.98, and the nearest resistance the Pivot at $1.05.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.7%/day
Key levels
$4.2352 week high+314.7%
$2.78200 day average+172.5%
$2.39100 day average+134.3%
$1.8350 day average+79.4%
$1.55Swing high (Nov 9)+52.0%
$1.4020 day average+37.3%
$1.13Pivot R1+10.8%
$1.05Pivot+2.9%
$1.02Last close
$0.9852 week low−3.9%
$0.95Pivot S1−6.9%
Indicators
RSI (14)27.93Oversold below 30Oversold
MACD-0.18Below its signal lineBearish
Stochastic10.0Near the bottom of its rangeOversold
ADX (14)37.1Trending down
Williams %R-94.1Oversold below −80, overbought above −20Oversold
CCI (20)-235.5Oversold below −100, overbought above 100Oversold
Rate of change−28.2%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 14.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CABA

What happened before

See how CABA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CABA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CABA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CABA in the last 90 days.

Loading…

See today’s whale options flow across the market →

CABA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲105 buying vs 47 selling
  • ▲Held by funds +13.9 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding163141+15.6%
In funds' top 1001−100.0%
Held by funds87.5%73.6%+13.9 pts
New / increased35 / 7055 / 500.0%
Reduced / sold out34 / 1320 / 23+9.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CABA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CABA is in one of them and how their past CABA trades turned out.

CABA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CABA in an article yet. Here's the latest on the wider market.

About Cabaletta Bio

Cabaletta Bio is a biotechnology company based in Philadelphia, Pennsylvania, that develops engineered T cell therapies for people with autoimmune diseases. Its lead candidate, rese-cel, is a CAR T cell treatment designed to deplete B cells, and it is in clinical trials for conditions including myositis, lupus, systemic sclerosis and generalized myasthenia gravis. The company does not yet sell a commercial product, and the patients it aims to serve are people living with these conditions.

Headquarters
Philadelphia, PA